The COVID-19 infection was found to be harmful specially to those with underlying cardiovascular diseases which maybe due to upregulation of Angiotensin-converting enzyme 2 expression that may lead to increased SARS-CoV-2 virulence. Renin Angiotensin System Inhibitor (RASI) acts by blocking the angiotensin-converting enzyme and angiotensin II type 1 receptors that affects the production of the ACE2 protein. Given the widespread use of RASIs and that they are generally cardioprotective, research into the safety and therapeutic efficacy of continuing these maintenance medications in hospitalized mild to moderate COVID-19 patients is immensely needed. This study explored the association of in-hospital discontinuation of maintenance RASI on all-cause mortality & ICU admission among hypertensive patients admitted for mild to moderate COVID- 19 infection.